Lutsiak ME - Search Results

1

Immune consequences of protracted host-tumor interactions in a transgenic mouse model of mammary carcinoma.

Stewart TJ, Lutsiak ME, Abrams SI. Stewart TJ, et al. Among authors: lutsiak me. Cancer Invest. 2008 Apr-May;26(3):237-49. doi: 10.1080/07357900701708419. Cancer Invest. 2008. PMID: 18317964 Free article.

2

Immunological responses can have both pro- and antitumour effects: implications for immunotherapy.

Stewart TJ, Greeneltch KM, Lutsiak ME, Abrams SI. Stewart TJ, et al. Among authors: lutsiak me. Expert Rev Mol Med. 2007 Feb 7;9(4):1-20. doi: 10.1017/S1462399407000233. Expert Rev Mol Med. 2007. PMID: 17284328 Review.

3

Tumor-induced impairment of TCR signaling results in compromised functionality of tumor-infiltrating regulatory T cells.

Lutsiak ME, Tagaya Y, Adams AJ, Schlom J, Sabzevari H. Lutsiak ME, et al. J Immunol. 2008 May 1;180(9):5871-81. doi: 10.4049/jimmunol.180.9.5871. J Immunol. 2008. PMID: 18424706 Free PMC article.

4

TGF-beta modulates the functionality of tumor-infiltrating CD8+ T cells through effects on TCR signaling and Spred1 expression.

di Bari MG, Lutsiak ME, Takai S, Mostböck S, Farsaci B, Semnani RT, Wakefield LM, Schlom J, Sabzevari H. di Bari MG, et al. Among authors: lutsiak me. Cancer Immunol Immunother. 2009 Nov;58(11):1809-18. doi: 10.1007/s00262-009-0692-9. Epub 2009 Mar 25. Cancer Immunol Immunother. 2009. PMID: 19319531 Free PMC article.

5

IL-2/anti-IL-2 antibody complex enhances vaccine-mediated antigen-specific CD8+ T cell responses and increases the ratio of effector/memory CD8+ T cells to regulatory T cells.

Mostböck S, Lutsiak ME, Milenic DE, Baidoo K, Schlom J, Sabzevari H. Mostböck S, et al. Among authors: lutsiak me. J Immunol. 2008 Apr 1;180(7):5118-29. doi: 10.4049/jimmunol.180.7.5118. J Immunol. 2008. PMID: 18354238

6

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide.

Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Lutsiak ME, et al. Blood. 2005 Apr 1;105(7):2862-8. doi: 10.1182/blood-2004-06-2410. Epub 2004 Dec 9. Blood. 2005. PMID: 15591121 Free article.

7

Construction and preclinical characterization of Fc-mGITRL for the immunotherapy of cancer.

Hu P, Arias RS, Sadun RE, Nien YC, Zhang N, Sabzevari H, Lutsiak ME, Khawli LA, Epstein AL. Hu P, et al. Among authors: lutsiak me. Clin Cancer Res. 2008 Jan 15;14(2):579-88. doi: 10.1158/1078-0432.CCR-07-0940. Clin Cancer Res. 2008. PMID: 18223234

8

Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models.

Sadun RE, Hsu WE, Zhang N, Nien YC, Bergfeld SA, Sabzevari H, Lutsiak ME, Khawli L, Hu P, Epstein AL. Sadun RE, et al. Among authors: lutsiak me. J Immunother. 2008 Apr;31(3):235-45. doi: 10.1097/CJI.0b013e31816a88e0. J Immunother. 2008. PMID: 18317364

9

Poly(D,L-lactic-co-glycolic acid) microsphere delivery of adenovirus for vaccination.

Wang D, Molavi O, Lutsiak ME, Elamanchili P, Kwon GS, Samuel J. Wang D, et al. Among authors: lutsiak me. J Pharm Pharm Sci. 2007;10(2):217-30. J Pharm Pharm Sci. 2007. PMID: 17706180 Free article.

10

Biodegradable nanoparticle delivery of a Th2-biased peptide for induction of Th1 immune responses.

Lutsiak ME, Kwon GS, Samuel J. Lutsiak ME, et al. J Pharm Pharmacol. 2006 Jun;58(6):739-47. doi: 10.1211/jpp.58.6.0004. J Pharm Pharmacol. 2006. PMID: 16734975

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12 results

Search Page

Filters